Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24664580 | 0.83 | DGAT1 (0.55) | DGAT1HPGDALDH1A1KMT2ANPC1 | |
| SCHEMBL16960361 | 0.83 | DGAT1 (0.44) | DGAT1CES2HPGDGALR3CYP1A2 | |
| SCHEMBL10082 | 0.79 | DGAT1 (0.50) | DGAT1CES2HPGDGALR3CYP1A2 | |
| SCHEMBL30374539 | 0.79 | DGAT1 (0.50) | DGAT1CES2HPGDGALR3CYP1A2 | |
| SCHEMBL12273203 | 0.79 | DGAT1 (0.41) | DGAT1CES2HPGDGALR3CYP1A2 | |
| SCHEMBL16952184 | 0.79 | DGAT1 (0.38) | DGAT1CES2HPGDGALR3CYP1A2 | |
| SCHEMBL20271806 | 0.79 | DGAT1 (0.38) | DGAT1CES2HPGDGALR3CYP1A2 | |
| SCHEMBL11042341 | 0.78 | CES2 (0.56) | CES2HPGDALDH1A1KMT2ANPC1 | |
| SCHEMBL20835362 | 0.78 | POLB (0.40) | CES2HPGDGALR3CYP1A2CYP2C9 | |
| SCHEMBL16958285 | 0.78 | DGAT1 (0.44) | DGAT1CES2HPGDGALR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399995-B2 | 1,4-Oxazines useful as selective BACE1 inhibitors | ELI LILLY AND COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399995-B2 | 1,4-Oxazines useful as selective BACE1 inhibitors | ELI LILLY AND COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3504211-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | Eli Lilly and Company (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20190161502-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | LILLY CO ELI (US) | 2019-05-30 | — | — | US | disclosed |
| US-20190161502-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | LILLY CO ELI (US) | 2019-05-30 | — | — | US | disclosed |
| WO-2018039062-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | ELI LILLY AND COMPANY (US) | 2018-03-01 | — | — | WO | disclosed |
| WO-2018039062-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | ELI LILLY AND COMPANY (US) | 2018-03-01 | — | — | WO | disclosed |
| EP-2663559-B1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| EP-2456763-B1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-15 | — | — | US | disclosed |
| US-8207164-B2 | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | disclosed |
| EP-2456763-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A. (IT) | 2011-12-22 | — | — | US | disclosed |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A. (IT) | 2011-12-22 | — | — | US | disclosed |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A. (IT) | 2011-12-22 | — | — | US | disclosed |
| WO-2011138293-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011138293-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-10 | — | — | WO | disclosed |
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG | 2011-01-27 | — | — | US | disclosed |
| WO-2011009943-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399995-B2 | 1,4-Oxazines useful as selective BACE1 inhibitors | BACE1, BACE2, PSEN1 | DGAT1 2151/4885CES2 1493/4885HPGD 3493/4885 |
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | DGAT1 3947/4885CES2 517/4885HPGD 224/4885 |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | BACE2, BACE1, PSEN2 | DGAT1 3131/4885CES2 919/4885HPGD 2609/4885 |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | DGAT1 3947/4885CES2 517/4885HPGD 224/4885 |
| US-20190161502-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | BACE1, BACE2, PSEN1 | DGAT1 2151/4885CES2 1493/4885HPGD 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.